Platinum Biologics

Name

Platinum Biologics

Legal name

Platinum Biologics

Website

https://platinumbiologics.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Regenerative Biologics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Blood and Organ Banks (621991)

SIC

Biological Products, (No Disgnostic Substances) (2836), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Biologic API/Drug Substance Manufacturing Services (HLAAAKAA)

akta.pro secondary industries

Biologics & Biosimilars Distributors (HLAIAJAH), Specialty Pharmacy & Biologics Distribution (CRAOAHAD)

Keywords

• Regenerative biologics
• Wharton's Jelly products
• Exosome formulations
• Perinatal tissue biologics
• Human tissue allografts

Headquarters

HQ city

Orlando

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

1. Biologics Product Sales: Revenue generated from sale of regenerative biologics products to healthcare providers including Nano PRP Jelly, Nano Flex, Nano Xsomes, Nano EX, Nano Flow, Nano AER, Nano AER Plus, and Nano DPM. Products are sold directly to physicians, clinics, and hospitals with pricing available through authenticated portal access.
2. Distributor Network Commissions: Commissions paid to independent sales reps and distributors who sell Platinum Biologics products to healthcare providers. The company operates a plug-and-play sales system with weekly pay schedule and commission escrow system. No fees, quotas, or long onboarding for distributors.
3. Group Purchasing Organization (GPO) Fees: As a physician-centric GPO, the company provides tailored biologics solutions to healthcare providers with individualized support throughout the product selection, education, and application process.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

Platinum Biologics is a physician-centric Group Purchasing Organization (GPO) that manufactures and distributes human perinatal-derived regenerative biologics, including Wharton's Jelly-based scaffold products and umbilical cord blood-derived exosome formulations, to healthcare providers nationwide. Products are produced in FDA-registered, cGMP-compliant, ISO Class cleanrooms following AATB and AABB guidelines, and are sold to physicians, clinics, and surgery centers for orthopedic, pain management, functional medicine, and regenerative applications.

Product overview

Platinum Biologics is a physician-centric Group Purchasing Organization (GPO) specializing in regenerative biologics derived from human perinatal tissues. The company operates FDA-registered, cGMP-compliant facilities and offers a portfolio of Wharton's Jelly-based scaffold products and exosome formulations for clinicians nationwide. The core product portfolio includes Nano PRP Jelly (70mg/3mL Wharton's Jelly scaffold), Nano Flex (300mg concentrated Wharton's Jelly), Nano Flow (extracellular matrix), Nano DPM (advanced regenerative formula), and Nano AER/Nano AER Plus (concentrated blends), along with exosome products Nano Xsomes (cord blood-derived) and Nano EX (shelf-stable umbilical cord-derived with 30 billion lyophilized exosomes). Products serve orthopedics, pain clinics, functional medicine, surgery centers, and regenerative practices.

Differentiator

Problem solved

Functional benefit

Products and services

• Nano PRP Jelly A ready-to-use pure Wharton's Jelly scaffold product in a 3mL vial with 70mg tissue weight, designed for regenerative medicine practitioners seeking consistent, off-the-shelf biologic material that eliminates traditional PRP spinning preparation.
• Nano Flex The most concentrated Wharton's Jelly product in the portfolio, offering 300mg of tissue in a 2mL vial for medical professionals seeking maximum potency in regenerative applications.
• Nano Xsomes Cord blood-derived exosome formulation developed using human progenitor endothelial stem cell (hPESC) technology, characterized by ELISA, nanoparticle tracking analysis, and single particle interferometric reflectance imaging sensing, containing biologically active growth factors including IGFBP, growth hormone, PDGF-AA, TGF-beta1, VEGF, and IL-1RA.
• Nano EX A shelf-stable, umbilical cord-derived exosome blend containing 30 billion lyophilized exosomes along with placental growth factors, vascular endothelial growth factors, and transforming growth factors, requiring no refrigeration and produced via a specialized lyophilization process.
• Nano Flow A Wharton's Jelly-derived extracellular matrix formulation designed for biological scaffold evaluations, structural matrix studies, and regenerative science applications, available in 1mL and 2mL vial formats.
• Nano AER A premium concentrated formula in a 1mL vial format developed for advanced composition quality, dependable consistency, and streamlined handling in professional environments.
• Nano AER Plus A premium high-concentration formula in a 1mL vial format designed for advanced cellular support with refined composition standards and professional-grade presentation.
• Nano DPM An advanced regenerative research formula developed for professionals seeking innovative solutions for regenerative and cellular research applications, with consistent quality and modern processing standards.

Quantifiable outcome

• Outcome guarantee: If patient doesn’t achieve at least 50% improvement, physician receives free product for reapplication at zero cost
• +3 more outcomes

Named customers3 records

Segments6 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators3 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• BioExosome: BioExosome specializes in exosome-based regenerative products, directly overlapping with Platinum Biologics' Nano Xsomes and Nano EX product lines. They serve a similar physician customer base in orthopedics, aesthetics, and wellness.
• Apex Biologix: Apex Biologix is a regenerative medicine distributor offering Wharton's Jelly, exosome, and PRP products to healthcare providers. Their physician-direct sales model and product mix substantially overlap with Platinum Biologics' offering.
• Predictive Biotech: Predictive Biotech distributes perinatal tissue allografts including Wharton's Jelly and amniotic membrane products to physicians nationwide. Their product portfolio and direct-to-physician distribution model closely parallel Platinum Biologics' go-to-market approach.
• Regenative Labs: Regenative Labs produces Wharton's Jelly and amniotic membrane products for regenerative medicine, directly competing with Platinum Biologics in the same perinatal tissue category. Both serve orthopedic, pain management, and wound care physicians with similar scaffold and flowable product formats.
• Vivex Biologics: Vivex Biologics develops and distributes regenerative tissue products including amniotic and umbilical cord-derived biologics for orthopedic, wound care, and pain management applications. They are a direct competitor in the perinatal tissue biologics space.

Broad incumbents

• MiMedx Group: MiMedx produces amniotic membrane-based tissue grafts for wound care, surgical, and sports medicine applications. They are an established publicly-traded competitor with broader market reach and FDA-cleared products in adjacent indications.
• Organogenesis Holdings: Organogenesis (NASDAQ: ORGO) is an established publicly-traded regenerative medicine company offering wound care and surgical biologics. While their portfolio is broader and FDA-approved for specific indications, they compete in the same hospital and physician channels for regenerative tissue products.
• Vericel Corporation: Vericel (NASDAQ: VCEL) is a publicly-traded cellular therapy and specialty biologics company with FDA-approved products in orthopedics and severe burns. They represent an established incumbent in regenerative medicine with full regulatory approvals that Platinum Biologics does not currently hold.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/PBiologics56664
• Facebookfacebook.com/platinumbiologics

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Platinum Biologics